Abstract: An electronic device includes an energy storage unit, a charge pump circuit, a charging circuit, and a controller. The charge pump circuit is electrically connected to the power supply, and the power supply is configured to receive the input electrical energy. The charging circuit is electrically connected between the charge pump circuit and the energy storage unit. The controller is electrically connected with the power supply, the charge pump circuit, and the charging circuit respectively, and the controller controls the charge pump circuit and the charging circuit to switch among a plurality of charging modes according to compatibility information of the power supply.

Abstract: The invention provides a pH-sensitive linker that can simultaneously bind metallic nanoparticles and one or more agents with various molecular size. The linker of the invention can deliver the agents into cells involved in disease processes or close to cells so that the agents can selectively target and effect on the cells. The target delivery provided by the linker of the invention can be used for example for disease sensing, imaging, drug delivery, and therapy.

Abstract: A power module may be attached to and detached from a network extender. The power module may include one or more power connectors that are specific to one or more countries/regions. The power module may include one or more other interfaces (e.g., Ethernet port, etc.). The power module may include a power connector and a male local area network connector on a first surface. The power module may include a local area network port on a second surface, wherein the local area network port is conductively connected to the male local area network connector via a local area network port access.

Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.

Abstract: In a data transmission process of a heterogeneous LWA network, the base station device receives a series of data packets and a signal intensity information. A communication address of each of the series of data packet is directed to a specified user mobile device, and the signal intensity information indicates an intensity of a signal transmitted between the specified user mobile device and a wireless network access point device in communication with the base station device and the specified user mobile device. If the signal intensity information complies with a first specific condition and a status of data transmission associated with the user mobile device complies with a second specific condition, partial data packets are assigned to be transferred to the user mobile device by the wireless network access point device, and partial data packets are assigned to be transferred to the user mobile device by the base station device.

Abstract: A power supply device includes a PF correction circuit, a power switching circuit and a control circuit. The PF correction circuit converts an input voltage to a bus voltage according to a control signal to supply a later stage circuit. The power switching circuit selectively switches to conduct a first source or a second source to the PF correction circuit to provide the input voltage to the PF correction circuit. The control circuit outputs the control signal to the PF correction circuit. When the control circuit detects a first voltage of the first source connecting to the PF correction circuit is abnormal, the control circuit determines whether a second voltage of the second source is smaller than the bus voltage and controls the power switching circuit to switch when the second voltage is smaller than the bus voltage to conduct the second source to the PF correction circuit.

Abstract: A method of generating recommendations based on predicted activity external to a first region includes segmenting a plurality of users into at least a first subset of users and a second subset of users. The method also includes generating an activation metric for each user of the first and second subset of users. The method also includes determining a plurality of target users from the plurality of users. The method also includes automatically initiating a target action for each target user. A system and computer program product for generating recommendations based on predicted activity external to a first region is also disclosed.

Abstract: Various embodiments of the present disclosure are directed towards a method for forming a fully silicided (FUSI) gated device, the method including: forming a masking layer onto a gate structure over a substrate, the gate structure comprising a polysilicon layer. Forming a first source region and a first drain region on opposing sides of the gate structure within the substrate, the gate structure is formed before the first source and drain regions. Performing a first removal process to remove a portion of the masking layer and expose an upper surface of the polysilicon layer. The first source and drain regions are formed before the first removal process. Forming a conductive layer directly contacting the upper surface of the polysilicon layer. The conductive layer is formed after the first removal process. Converting the conductive layer and polysilicon layer into a FUSI layer. The FUSI layer is thin and uniform in thickness.

Abstract: Disclosed are compounds of Formula (I) Formula (I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[1,2-b]pyridazin-3-yl, and pyrazolo[1,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Abstract: An allocation method of communication resources is use with at least a user mobile device, at least first and second wireless network access point devices, and a base station device for mobile communication. In the allocation method, the base station device receives a registration request from the user mobile device; and the base station device determines an order of the first and second wireless network access point devices for the user mobile device to register in according to intensities of signals of the first and second wireless network access point devices, which are measured by the user mobile device, and counts of user mobile devices having registered in the first and second wireless network access point devices, respectively.

Abstract: A power module may be attached to and detached from a network extender. The power module may include one or more power connectors that are specific to one or more countries/regions. The power module may include one or more other interfaces (e.g., Ethernet port, etc.). The power module may include a power connector and a male local area network connector on a first surface. The power module may include a local area network port on a second surface, wherein the local area network port is conductively connected to the male local area network connector via a local area network port access.

Abstract: A charging circuit applied to a post-stage circuit includes a power converting circuit, a power storage circuit, a switching circuit and a processing circuit. The power converting circuit receives an external voltage and converts the external voltage to a charging voltage. The power storage circuit is coupled to the power converting circuit and receives the charging voltage to store the power. The switching circuit is coupled to the power converting circuit and the power storage circuit. The processing circuit is coupled to the switching circuit and controls the charging circuit operated in a first mode or a second mode. When operated in the first mode, the external voltage supplies power to the post-stage circuit. When operated in the second mode, the charging voltage supplies power to the post-stage circuit.

Abstract: An exercise state evaluation method having the following steps is provided. The steps includes: obtaining a plurality of sensing signals by a foot information sensing module; recording a receiving time of each of the sensing signals by a processing unit and generating a plurality of pressure values, a plurality of center of gravity values, and a center of gravity trajectory information corresponding a human body according to each of the sensing signals; determining a start time, an acting time and a finish time corresponding to an exercise according to the receiving time, the pressure values, the center of gravity values and the center of gravity trajectory information; obtaining an act time value according to the start time, the acting time and the finish time; and integrating the pressure values, the center of gravity values, the center of gravity trajectory information and the act time value to an user interface.

Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).

Abstract: A method for processing a plurality of semiconductor wafers includes acquiring a process parameter measurement for each of the semiconductor wafers, associating each of the semiconductor wafers with one of a plurality of groups based on a respective process parameter measurement for each of the semiconductor wafers, where each respective group corresponds to a respective recipe, and for each one of the groups, processing ones of the semiconductor wafers associated with that group together according to a respective recipe.

Abstract: Disclosed are compounds of Formula (I) Formula (I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[1,2-b]pyridazin-3-yl, and pyrazolo[1,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

Abstract: A power module may be attached to and detached from a network extender. The power module may include one or more power connectors that are specific to one or more countries/regions. The power module may include one or more other interfaces (e.g., Ethernet port, etc.). The power module may include a power connector and a male local area network connector on a first surface. The power module may include a local area network port on a second surface, wherein the local area network port is conductively connected to the male local area network connector via a local area network port access.